Precipio, Inc. (NASDAQ: PRPO)

Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly hematologic malignancies, to address the systemic issue of disease misdiagnosis. The company operates at the intersection of clinical laboratory services and proprietary diagnostic product development, aiming to enhance diagnostic accuracy, accessibility, and workflow efficiency. Precipio’s integrated model leverages its pathology services to fund and accelerate research and development, creating a self-sustaining cycle of innovation and commercialization in oncology diagnostics.

Precipio generates revenue through two primary channels: diagnostic testing services and the sale of proprietary diagnostic products. The pathology services division provides specialized cancer diagnostic testing, including molecular diagnostics and cytogenetics, to physicians, hospitals, and laboratories, with reimbursement primarily from Medicare, Medicaid, and private insurers. The products division commercializes proprietary assays and diagnostic kits, such as HemeScreen and IV-Cell, which are sold to clinical laboratories to improve testing accuracy and operational efficiency. Revenue from products offers scalability, though adoption depends on regulatory approvals, reimbursement policies, and market demand.

The company operates through the following divisions:

• Pathology Services Division: This division delivers specialized diagnostic testing for hematologic cancers, including molecular diagnostics, cytogenetics, and advanced laboratory analyses. It operates two full-service laboratories equipped to process patient samples daily, providing pathology reports to healthcare providers. The division serves as an internal clinical environment for developing, testing, and validating new diagnostic products while generating recurring service revenue. It also facilitates direct engagement with clinicians and access to patient samples, which informs product development.

• Products Division: This division focuses on developing and commercializing proprietary diagnostic assays and kits designed for use by external clinical laboratories. Key activities include assay development, validation, manufacturing, and distribution through laboratory partners and commercial channels. The division’s offerings, such as HemeScreen and IV-Cell, aim to improve laboratory workflow efficiency, reduce testing turnaround times, and lower operational costs for customers. Product revenues are scalable but subject to regulatory and market adoption risks.

Precipio occupies a distinctive position within the oncology diagnostics industry by combining clinical laboratory operations with product development. Its integrated model provides a competitive edge, enabling rapid and cost-efficient innovation through direct access to patient samples, clinical feedback, and operational infrastructure. Key competitors in pathology services include NeoGenomics Laboratories, GenPath Diagnostics, LabCorp, and Quest Diagnostics, while product competitors range from reagent manufacturers like Qiagen and BioRad to next-generation sequencing providers such as Illumina and Roche. Precipio’s advantages stem from its ability to develop clinically relevant, workflow-optimized solutions that address gaps in diagnostic accuracy and laboratory economics, positioning it as a niche player with potential for broader market adoption.

Precipio serves a diverse customer base, including physicians, hospitals, clinical laboratories, and oncology practices across over 20 U. S. states. Its pathology services division primarily caters to healthcare providers requiring specialized cancer diagnostics, while the products division targets clinical laboratories seeking cost-effective, efficient diagnostic tools. The company’s technologies, such as HemeScreen and IV-Cell, are designed to improve diagnostic precision and reduce misdiagnosis rates, appealing to institutions focused on value-based care and operational efficiency.